HY-133 is under clinical development by HyPharm and currently in Phase I for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections. According to GlobalData, Phase I drugs for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the HY-133 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HY-133 overview
HY-133 is under development for the treatment of Staphylococcus aureus infections like African methicillin susceptible and methicillin resistant S.aureus lineages, Staphylococcus schweitzeri, ceftaroline/ceftobiprole and borderline oxacillin-resistant infections. The drug candidate is a recombinant bacteriophage endolysin derived from specific viruses. It is formulated as hydrogel which is administered through nasal route. It is a new chemical entity developed based on phage recombinant protein technology. The drug candidate acts by targeting peptidoglycan.
HyPharm overview
HyPharm, is a operator of Innovative bacteriophage-based solutions. The company is headquartered in Germany.
For a complete picture of HY-133’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
